GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ContraFect Corp (OTCPK:CFRXQ) » Definitions » Operating Margin %

ContraFect (ContraFect) Operating Margin % : 0.00% (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is ContraFect Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. ContraFect's Operating Income for the three months ended in Sep. 2023 was $-6.68 Mil. ContraFect's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, ContraFect's Operating Margin % for the quarter that ended in Sep. 2023 was 0.00%.

The historical rank and industry rank for ContraFect's Operating Margin % or its related term are showing as below:


CFRXQ's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -175.525
* Ranked among companies with meaningful Operating Margin % only.

ContraFect's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

ContraFect's Operating Income for the three months ended in Sep. 2023 was $-6.68 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-30.21 Mil.


ContraFect Operating Margin % Historical Data

The historical data trend for ContraFect's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ContraFect Operating Margin % Chart

ContraFect Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ContraFect Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ContraFect's Operating Margin %

For the Biotechnology subindustry, ContraFect's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ContraFect's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ContraFect's Operating Margin % distribution charts can be found below:

* The bar in red indicates where ContraFect's Operating Margin % falls into.



ContraFect Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

ContraFect's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-56.889 / 0
= %

ContraFect's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=-6.677 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ContraFect  (OTCPK:CFRXQ) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


ContraFect Operating Margin % Related Terms

Thank you for viewing the detailed overview of ContraFect's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ContraFect (ContraFect) Business Description

Traded in Other Exchanges
N/A
Address
28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Executives
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Lishan Aklog director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Michael Messinger officer: VP Finance 238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534
Cary Sucoff director 1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904
David N. Low director EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Lisa Ricciardi director C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Joshua B Muntner officer: SVP Business Development 30 FIFTH AVENUE, 12F, NEW YORK NY 10011
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 10 percent owner BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233
Fosun Industrial Co., Ltd 10 percent owner FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000
Cara M Cassino officer: Chief Medical Officer 757 STONY POINT ROAD, BENSON VT 05743
Natalie Bogdanos officer: General Counsel 207-23 DARREN DRIVE, BAYSIDE NY 11360
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael J. Otto director 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421

ContraFect (ContraFect) Headlines

From GuruFocus